<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Stratification and doses of opioids for head and neck procedures</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Stratification and doses of opioids for head and neck procedures</h1>
<div class="graphic"><div class="figure"><div class="ttl">Stratification and doses of opioids for head and neck procedures</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1_left" colspan="3">Stratification of opioid infusions for head and neck surgery</td> </tr> <tr> <td class="subtitle2_left">Degree of postoperative pain</td> <td class="subtitle2_left" colspan="2">Opioid regimen</td> </tr> <tr> <td class="indent1">None to mild</td> <td colspan="2">Remifentanil infusion +/– fentanyl 1 mcg/kg total dose</td> </tr> <tr> <td class="indent1">Mild to moderate</td> <td colspan="2"> <p>Remifentanil infusion + fentanyl 1 to 3 mcg/kg total dose</p> <p class="indent1">OR</p> Alfentanil infusion</td> </tr> <tr class="divider_bottom"> <td class="indent1">Moderate to severe</td> <td colspan="2"> <p>Sufentanil infusion +/– remifentanil infusion*</p> <p class="indent1">OR</p> Fentanyl infusion +/– remifentanil infusion*</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="3">Opioid doses for head and neck surgery<sup>¶</sup><sup>[1-23]</sup></td> </tr> <tr> <td class="subtitle2_left">Opioid</td> <td class="subtitle2_left">IV load</td> <td class="subtitle2_left">IV infusion</td> </tr> <tr> <td class="indent1">Fentanyl</td> <td>3 to 7 mcg/kg<sup>Δ</sup></td> <td>0.7 to 2.5 mcg/kg/hour<sup>◊</sup></td> </tr> <tr> <td class="indent1">Sufentanil</td> <td>0.25 to 1.5 mcg/kg<sup>Δ</sup><br/> TCI: 0.4 to 0.5 ng/mL</td> <td>0.2 to 0.3 mcg/kg/hour<br/> TCI: 0.2 to 0.65 ng/mL</td> </tr> <tr> <td class="indent1">Alfentanil</td> <td>20 to 40 mcg/kg<br/> TCI: 100 to 200 ng/mL</td> <td>0.25 to 1.5 mcg/kg/minute<br/> TCI: 60 to 150 ng/mL</td> </tr> <tr> <td class="indent1">Remifentanil</td> <td>0.5 to 2 mcg/kg<br/> TCI: 4 ng/mL</td> <td>0.05 to 0.3 mcg/kg/minute<br/> TCI: 1.5 to 9 ng/mL</td> </tr> </tbody></table></div><div class="graphic_lgnd">TCI with opioids and propofol allows for easier and more rapid titration of drugs to patient responses and facilitates intraoperative hemodynamic control, as well as rapid recovery from anesthesia.</div><div class="graphic_footnotes">IV: intravenous; TCI: target-controlled infusion; TIVA: total IV anesthesia; N<sub>2</sub>O: nitrous oxide.<br/>* May be additionally required during highly stimulating parts of the surgical procedure.<br/>¶ Assumes: IV induction with propofol 1 to 2 mg/kg, maintenance of TIVA with propofol 80 to 180 mcg/kg/minute (TCI 3 to 5 mcg/mL), and no N<sub>2</sub>O administration.<br/>Δ We titrate the loading dose of fentanyl or sufentanil using the clinical endpoints during induction, such as either a decrease of respiratory rate or onset of sedation.<br/><span class="lozenge">◊</span> Fentanyl infusion should be used with caution and adjusted accordingly due to its long, context-sensitive half-life.</div><div class="graphic_reference">References:

<ol>
<li>Erhan E, Ugur G, Gunusen I, et al. Propofol - not thiopental or etomidate - with remifentanil provides adequate intubating conditions in the absence of neuromuscular blockade. Can J Anaesth 2003; 50:108.</li>
<li>Jellish WS, Leonetti JP, Avramov A, et al. Remifentanil-based anesthesia versus a propofol technique for otologic surgical procedures. Otolaryngol Head Neck Surg 2000; 122:222.</li>
<li>Eberhart LH, Eberspaecher M, Wulf H, et al. Fast-track eligibility, costs and quality of recovery after intravenous anaesthesia with propofol-remifentanil versus balanced anaesthesia with isoflurane-alfentanil. Eur J Anaesthesiol 2004; 21:107.</li>
<li>Philip BK, Kallar SK, Bogetz MS, et al. A multicenter comparison of maintenance and recovery with sevoflurane or isoflurane for adult ambulatory anesthesia. The Sevoflurane Multicenter Ambulatory Group. Anesth Analg 1996; 83:314.</li>
<li>Wuesten R, Van Aken H, Glass PS, et al. Assessment of depth of anesthesia and postoperative respiratory recovery after remifentanil- versus alfentanil-based total intravenous anesthesia in patients undergoing ear-nose-throat surgery. Anesthesiology 2001; 94:211.</li>
<li>Montes FR, Trillos JE, Rincón IE, et al. Comparison of total intravenous anesthesia and sevoflurane-fentanyl anesthesia for outpatient otorhinolaryngeal surgery. J Clin Anesth 2002; 14:324.</li>
<li>Jellish WS, Leonetti JP, Buoy CM, et al. Facial nerve electromyographic monitoring to predict movement in patients titrated to a standard anesthetic depth. Anesth Analg 2009; 109:551.</li>
<li>Vuyk J. Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. Acta Anaesth Belg 2001; 52:445.</li>
<li>Stanski DR, Shafer SL. Quantifying anesthetic drug interaction. Implications for drug dosing. Anesthesiology 1995; 83:1.</li>
<li>Twersky RS, Jamerson B, Warner DS, et al. Hemodynamics and emergence profile of remifentanil versus fentanyl prospectively compared in a large population of surgical patients. J Clin Anesth 2001; 13:407.</li>
<li>Miller DR, Martineau RJ, O'Brien H, et al. Effects of alfentanil on the hemodynamic and catecholamine response to tracheal intubation. Anesth Analg 1993; 76:1040.</li>
<li>Thompson JP, Hall AP, Russell J, et al. Effect of remifentanil on the haemodynamic response to orotracheal intubation. Br J Anaesth 1998; 80:467.</li>
<li>McAtamney D, O'Hare R, Hughes D, et al. Evaluation of remifentanil for control of haemodynamic response to tracheal intubation. Anaesthesia 1998; 53:1223.</li>
<li>Jeon YT, Oh AY, Park SH, et al. Optimal remifentanil dose for lightwand intubation without muscle relaxants in healthy patients with thiopental coadministration: a prospective randomised study. Eur J Anaesthesiol 2012; 29:520.</li>
<li>Demirkaya M, Kelsaka E, Sarihasan B, et al. The optimal dose of remifentanil for acceptable intubating conditions during propofol induction without neuromuscular blockade. J Clin Anesth 2012; 24:392.</li>
<li>Stefanutto TB, Feiner J, Krombach J, et al. Hemoglobin desaturation after propofol/remifentanil-induced apnea: a study of the recovery of spontaneous ventilation in healthy volunteers. Anesth Analg 2012; 114:980.</li>
<li>Gulhas N, Topal S, Erdogan Kayhan G, et al. Remifentanil without muscle relaxants for intubation in microlaryngoscopy: a double blind randomised clinical trial. Eur Rev Med Pharmacol Sci 2013; 17:1967.</li>
<li>Mencke T, Jacobs RM, Machmueller S, et al. Intubating conditions and side effects of propofol, remifentanil and sevoflurane compared with propofol, remifentanil and rocuronium: a randomised, prospective, clinical trial. BMC Anesthesiol 2014; 14:39.</li>
<li>Derrode N, Lebrun F, Levron JC, et al. Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. Br J Anaesth 2003; 9:842.</li>
<li>De Baerdemaeker LE, Jacobs S, Pattyn P, et al. Influence of intraoperative opioid on postoperative pain and pulmonary function after laparoscopic gastric banding: remifentanil TCI vs sufentanil TCI in morbid obesity. Br J Anaesth 2007; 99:404.</li>
<li>Bidgoli J, Delesalle S, De Hert SG, et al. A randomised trial comparing sufentanil versus remifentanil for laparoscopic gastroplasty in the morbidly obese patient. Eur J Anaesthesiol 2011; 28:120.</li>
<li>Vuyk J. TCI: supplementation and drug interactions. Anaesthesia 1998; 53 Suppl 1:35.</li>
<li>Pérus O, Marsot A, Ramain E, et al. Performance of alfentanil target-controlled infusion in normal and morbidly obese female patients. Br J Anaesth 2012; 109:551.</li>
</ol>

Courtesy of Dr. Vladimir Nekhendzy.</div><div id="graphicVersion">Graphic 108801 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
